Eng
 
 
Dragonite International Limited (Stock Code: 0329) is listed on the main board of the Hong Kong stock exchange (since April 2001) and formerly known as ‘Ruyan Group (Holdings) Limited’. The Group is principally engaged in the production and sale of health care and pharmaceutical products, as well as property and securities investment. The Group is also engaged in an ongoing and rigorous research and development program focusing on a broad range of innovative healthcare, and pharmaceutical.


Health Care Products
The Group commenced production of Chinese ginseng products under the brand name “Chenlong Baoling Longevity Ginseng” (辰龍保齡參) in 1991 and of American ginseng products under the brand names “Baoling Multi-vitamin Pill of American Ginseng” (保齡多維洋參丸) and “Baoling Lozenges of American Ginseng” (保齡洋參含片) in 1998 and 2000, respectively. With the establishment of new GMP grade production facilities, the Group plans to re-launch a new line of Ginseng products in the near future.




Pharmaceutical Products
The Group is increasing its investment in the development of pharmaceutical products constantly. In 2006, the Group completed the development and proceeded to the registration of a total of 15 new pharmaceutical products. Currently, the Group has obtained the production approval of “HaiTe Ling” (咳特靈) and commenced in production of it.  Besides, Amlodipine Besylate Tablets (苯磺酸氨地平) and Pidotimod Capsule (匹多莫德膠囊) have been granted the approval.